HOME > News > Press Releases > 2024.5.31 Glac Biotech’s Probiotic Business Set to Break NT$500 Million in Revenue — A Story of Growth, Strategy, and Gl
2024.5.31 Glac Biotech’s Probiotic Business Set to Break NT$500 Million in Revenue — A Story of Growth, Strategy, and Gl
On the last day of May, at a corporate forum hosted by Hua Nan Securities, Glac Biotech stepped back into the spotlight. For the first time since pausing its public listing plans in 2019 — and completing privatization in 2024 — the company stood before investors to share its story. And what a story it was.
“By April, we were already close to NT$200 million in revenue, with NT$270 million in orders in hand,” announced CEO Huang Sheng-Hung. “This year, we expect to cross the NT$500 million mark in probiotic business revenue. EBITDA has reached NT$33.8 million, a 254% year-on-year increase. With strong cash flow, profitability is now within reach.”
The audience leaned in. In a market often crowded with promises, Glac Biotech was presenting proof — hard numbers backed by steady growth.
From Domestic Pause to Global Expansion
The company’s journey has been shaped by bold decisions. In recent years, geopolitical shifts pushed Glac to pivot its focus from Mainland China to the global stage. This shift came with a commitment: to deliver premium probiotic powders, diverse formulations, and world-class processes as a one-stop solution for the world’s top nutrition brands.
And the strategy paid off. Since 2020, Glac’s revenue has climbed year after year — from NT$258 million in 2020 to NT$441 million in 2023. Now, with record orders and strong market momentum, Glac is positioned to cross the half-billion mark in 2024.
The Underdog That Became a Black Horse
What makes this even more compelling is Glac’s role within its parent group, Synmosa. Once considered a smaller player, Glac has emerged as the group’s “black horse,” capturing investor attention with rapid international expansion. Today, the majority of its revenue comes from overseas, and that share continues to grow steadily.
Chairman Lin Jung-Chin has led the company for 16 years with a simple belief: science must be the foundation. Guided by clinical validation, Glac has developed probiotics with proven health benefits, while also pioneering the field of postbiotics. In just a few short years, the company has outpaced older domestic and international rivals, collecting multiple health ingredient awards.
And the achievements don’t stop there. Glac was the first and only company to receive regulatory approval for probiotic strains suitable for infants in China. More recently, in May 2024, it became the only company in Taiwan with probiotics officially recognized as GRAS (Generally Recognized as Safe) by the U.S. FDA. These honors not only cement Glac’s leadership at home, but also bring international prestige to the entire group.
Growth Fueled by Innovation and Scale
Behind the numbers is a strategy of relentless innovation and smart partnerships. By building new collaboration models with major global clients, Glac has tapped into economies of scale — expanding production capacity, lowering costs, and boosting competitiveness.
The timing could not be better. The global probiotics market is on a steep growth curve, with a compound annual growth rate of 14% projected from 2023 to 2030. As populations age and consumers seek natural, non-pharmaceutical health solutions, demand for probiotics is set to soar.
Recognizing this momentum, Synmosa doubled down on health investments, completing a 100% acquisition of Glac Biotech in the first half of 2024. This was its second major bet in the health sector after Ausnutria Dairy, a clear sign of confidence.
Ready to Ride the Wave
For Glac Biotech, the path ahead is clear. With a solid scientific foundation, a robust global strategy, and the backing of a strong parent group, the company is poised not just to participate in the probiotic wave — but to lead it.
Investors left the forum with a sense of certainty: this was not just another health company chasing trends. This was a pioneer, ready to transform momentum into leadership, and numbers into a narrative of global success.
“By April, we were already close to NT$200 million in revenue, with NT$270 million in orders in hand,” announced CEO Huang Sheng-Hung. “This year, we expect to cross the NT$500 million mark in probiotic business revenue. EBITDA has reached NT$33.8 million, a 254% year-on-year increase. With strong cash flow, profitability is now within reach.”
The audience leaned in. In a market often crowded with promises, Glac Biotech was presenting proof — hard numbers backed by steady growth.
From Domestic Pause to Global Expansion
The company’s journey has been shaped by bold decisions. In recent years, geopolitical shifts pushed Glac to pivot its focus from Mainland China to the global stage. This shift came with a commitment: to deliver premium probiotic powders, diverse formulations, and world-class processes as a one-stop solution for the world’s top nutrition brands.
And the strategy paid off. Since 2020, Glac’s revenue has climbed year after year — from NT$258 million in 2020 to NT$441 million in 2023. Now, with record orders and strong market momentum, Glac is positioned to cross the half-billion mark in 2024.
The Underdog That Became a Black Horse
What makes this even more compelling is Glac’s role within its parent group, Synmosa. Once considered a smaller player, Glac has emerged as the group’s “black horse,” capturing investor attention with rapid international expansion. Today, the majority of its revenue comes from overseas, and that share continues to grow steadily.
Chairman Lin Jung-Chin has led the company for 16 years with a simple belief: science must be the foundation. Guided by clinical validation, Glac has developed probiotics with proven health benefits, while also pioneering the field of postbiotics. In just a few short years, the company has outpaced older domestic and international rivals, collecting multiple health ingredient awards.
And the achievements don’t stop there. Glac was the first and only company to receive regulatory approval for probiotic strains suitable for infants in China. More recently, in May 2024, it became the only company in Taiwan with probiotics officially recognized as GRAS (Generally Recognized as Safe) by the U.S. FDA. These honors not only cement Glac’s leadership at home, but also bring international prestige to the entire group.
Growth Fueled by Innovation and Scale
Behind the numbers is a strategy of relentless innovation and smart partnerships. By building new collaboration models with major global clients, Glac has tapped into economies of scale — expanding production capacity, lowering costs, and boosting competitiveness.
The timing could not be better. The global probiotics market is on a steep growth curve, with a compound annual growth rate of 14% projected from 2023 to 2030. As populations age and consumers seek natural, non-pharmaceutical health solutions, demand for probiotics is set to soar.
Recognizing this momentum, Synmosa doubled down on health investments, completing a 100% acquisition of Glac Biotech in the first half of 2024. This was its second major bet in the health sector after Ausnutria Dairy, a clear sign of confidence.
Ready to Ride the Wave
For Glac Biotech, the path ahead is clear. With a solid scientific foundation, a robust global strategy, and the backing of a strong parent group, the company is poised not just to participate in the probiotic wave — but to lead it.
Investors left the forum with a sense of certainty: this was not just another health company chasing trends. This was a pioneer, ready to transform momentum into leadership, and numbers into a narrative of global success.
Media Coverage (Extended Reading)
Business Today — May 31, 2024 (Chinese)
https://www.businesstoday.com.tw/article/category/183015/post/202405310024/
-
2024.7.23 Glac Biotech Unveils Next-Generation Probiotic Technology and Brain Health Innovations
-
2023.10.7 Caring for Women’s Health — Glac Biotech Joins Taiwan Cancer Foundation’s Pink Walk
-
2023.3.23 Beyond Nitrogen — Glac Biotech’s Exclusive Probiotic OEM Technology Locks in Freshness and Quality
-
2023.12.28 Over 90% Global Reorder Rate — Glac Biotech Becomes the Dark Horse of the Health Ingredient Supply Chain, Poi